Kaushal Parikh
Medical Oncology · Rochester, MNNPI 1710231006
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,681 of the $55,364 with a category attached, or 77.1%. 20 manufacturers reported payments, led by AstraZeneca at 34.7% of the total. 2025 is the largest year on record at $13,560, more than ten times the $127 reported in 2019.
Across 54 payments — averaging $1025.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Jazz Pharmaceuticals Inc.$4K
- Regeneron Healthcare Solutions, Inc.$4K
- Rigel Pharmaceuticals, Inc.$3K
- Blueprint Medicines Corporation$3K
- plus $15K from 14 others
Across 14 payments — averaging $56,872 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$376K
- Regeneron$153K
- Merck$147K
- Amgen$92K
- Mirati Therapeutics, Inc.$18K
- Verastem, Inc.$10K
What the payments were for
- Consulting fees$42,68177%
- Speaking & faculty fees$11,10020%
- Travel & lodging$8061%
- Food & beverage$7211%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $19,236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $6,120 |
| Jazz Pharmaceuticals Inc. | 3 | $4,292 |
| Regeneron Healthcare Solutions, Inc. | 3 | $3,949 |
| Rigel Pharmaceuticals, Inc. | 7 | $3,369 |
| Blueprint Medicines Corporation | 2 | $3,340 |
| EMD Serono, Inc. | 1 | $3,325 |
| Immunitybio, Inc. | 2 | $2,935 |
| Beigene, Ltd. | 1 | $1,650 |
| Merck | 5 | $1,567 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Janssen Scientific Affairs, LLC | 2 | $1,400 |
| Johnson & Johnson | 5 | $1,384 |
| Pfizer | 4 | $1,047 |
| Genentech USA, Inc. | 1 | $127 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Genentech, Inc. | 1 | $38 |
| AbbVie | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,364 in reported general payments places this provider in the 85th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 44 | $725,723 |
| AlecensaAlectinib Hcl | 24 | $487,811 |
| XareltoRivaroxaban | 17 | $14,847 |
| EliquisApixaban | 22 | $13,647 |
| Olanzapine | 35 | $380 |
| Prochlorperazine Maleate | 35 | $319 |
| Dexamethasone | 55 | $292 |
| Ondansetron Hcl | 29 | $197 |
| Levothyroxine Sodium | 15 | $108 |
| Prednisone | 19 | $46 |
| Lorazepam | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $19,236 | $725,72344 claims |
| Genentech USA, Inc.Alecensa | $127 | $487,81124 claims |
| Johnson & JohnsonXarelto | $1,384 | $14,84717 claims |
| PfizerEliquis | $1,047 | $13,64722 claims |
| Lilly USA, LLCOlanzapine | $12 | $38035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 133 medical oncology providers in Minnesota.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.